Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Dec 9, 2002
Current as of December 03, 2023
This is an open label study to determine the effects of the administration of Interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculosis mycobacterial infections. The study drug (interferon gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year. We may also collect blood from the relatives of these patients and normal volunteers in order to characterize the genetic basis, if any, of our patients' disorders.
- Demonstrated non-tuberculous mycobacterial infection, either disseminated or pulmonary.
- Received medical treatment for at least 3 months without improvement.
- Preserved renal, hepatic and hematologic function.
- Negative pregnancy urine and effective contraceptive.
- Age range greater than 5.
- No secondary immunodeficiency such as HIV or malignancy.
- Not currently receiving cytotoxic therapy within the past 3 months.
- Not pregnant or lactating.
- No seizure disorders.
- No known symptomatic cardiac disease.
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
All reviews come from applied patients